Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at email@example.com.
A Knack for Problem-Solving | 2023 Emerging Pharma Leader
The recipe for cross-functional collaboration in drug development. (The story of Justin To, chief operating officer, skeletal dysplasias and gene therapy, for Bridge Bio and a 2023 Emerging Pharma Leader.)
AI is a Tool, Not a Replacement for Employees
The pluses for pharma are many—alongside experienced workers.
New Reports Reveals Economic Challenges For Life Sciences Industry
The UK BioIndustry Association and Clarivate detail current economic trends in the UK Biotech Financing Report.
An Industry View on KOLs: Adapting to the New Norm in Interaction and Support
After the pandemic forced fundamental changes in the ways pharma and key opinion leaders worked together, both groups are using what they learned for a more seamless connection.
Balancing Pharma Hiring Practices in Good Times and Bad
The importance of not over-expanding during development, launch.
A New Era of Influence: Embracing the KOL-DOL Dynamic in Healthcare
How pharma companies can leverage the lessons learned during the pandemic around key opinion leaders and digital opinion leaders, respectively, to best use new channels of communication. Can both coexist across the healthcare engagement spectrum?
The Pivot to Digital
Chronicling Davidek Herron’s career crossover from playing professional basketball to leading Roche’s digital transformation and scale-up efforts—and the team lessons learned along the way.
Focus and Fundamentals: CFO Strategies on the Journey to Commercialization
Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.
One Way to Turn Economic Tide: New Innovation
Biopharma insiders believe it’s time to invest in technology again.
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.
Co-creating New Innovations
Pharma companies are teaming with academic institutions earlier in the R&D process.
Business and Passion
Kimberly Moran, head of rare diseases in the US for UCB, started off working in medicine but quickly learned the importance of the business side of industry—and its role in helping improve the diagnosis and access paths for underserved patient segments.
Pharma Needs to Look Internally for New Leadership
Companies should search within to gain talent edge.
Whole-Person Care: Are We Ready? The Intersection of Pharma and Digital Therapeutics
Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences companies, payers, and others in harnessing a healthcare future that will be increasingly dominated by holistic treatment and delivery.
Digital Biomarkers Could Reshape CNS Diagnosis, Treatment
AI drives new signal-detection efforts in Alzheimer’s and ALS.
Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants
Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
More Than a Name: Vyvgart
Launch of novel drug for rare neuromuscular disorder seeks to give voice to the patients.
Tricks for Navigating The ‘Talent War’ In Life Sciences
How companies can adapt to today’s fast-changing hiring climate.
Pharma’s Training Transformation: COVID Forces Compliance Revamp, Re-education
How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.
Milestones and Momentum: Assessing Advancements in Personalized Medicine
The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.
AI Opens Door To Improving Patient Experience
The technology is not just about digital enablement anymore.
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog.
IQVIA Releases Global Oncology Trend Report for 2022
While patients continue to benefit from increased product launches, the pandemic is still having an impact on caseload.
2 Commerce Drive Cranbury, NJ 08512